IBDEI0YN ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16267,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16267,1,3,0)
 ;;=3^Cardiomyopathies NEC
 ;;^UTILITY(U,$J,358.3,16267,1,4,0)
 ;;=4^I42.8
 ;;^UTILITY(U,$J,358.3,16267,2)
 ;;=^5007199
 ;;^UTILITY(U,$J,358.3,16268,0)
 ;;=I65.29^^61^729^10
 ;;^UTILITY(U,$J,358.3,16268,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16268,1,3,0)
 ;;=3^Carotid Artery Occlusion/Stenosis,Unspec
 ;;^UTILITY(U,$J,358.3,16268,1,4,0)
 ;;=4^I65.29
 ;;^UTILITY(U,$J,358.3,16268,2)
 ;;=^5007363
 ;;^UTILITY(U,$J,358.3,16269,0)
 ;;=I23.0^^61^729^11
 ;;^UTILITY(U,$J,358.3,16269,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16269,1,3,0)
 ;;=3^Certain Sequelae of MI
 ;;^UTILITY(U,$J,358.3,16269,1,4,0)
 ;;=4^I23.0
 ;;^UTILITY(U,$J,358.3,16269,2)
 ;;=^5007094
 ;;^UTILITY(U,$J,358.3,16270,0)
 ;;=I82.509^^61^729^12
 ;;^UTILITY(U,$J,358.3,16270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16270,1,3,0)
 ;;=3^Chr DVT/Embolism Lower Extremity,Unspec
 ;;^UTILITY(U,$J,358.3,16270,1,4,0)
 ;;=4^I82.509
 ;;^UTILITY(U,$J,358.3,16270,2)
 ;;=^5133628
 ;;^UTILITY(U,$J,358.3,16271,0)
 ;;=K70.0^^61^729^13
 ;;^UTILITY(U,$J,358.3,16271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16271,1,3,0)
 ;;=3^Chronic Liver Disease
 ;;^UTILITY(U,$J,358.3,16271,1,4,0)
 ;;=4^K70.0
 ;;^UTILITY(U,$J,358.3,16271,2)
 ;;=^5008784
 ;;^UTILITY(U,$J,358.3,16272,0)
 ;;=E56.1^^61^729^29
 ;;^UTILITY(U,$J,358.3,16272,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16272,1,3,0)
 ;;=3^Vitamin K Deficiency
 ;;^UTILITY(U,$J,358.3,16272,1,4,0)
 ;;=4^E56.1
 ;;^UTILITY(U,$J,358.3,16272,2)
 ;;=^5002801
 ;;^UTILITY(U,$J,358.3,16273,0)
 ;;=Z96.649^^61^729^14
 ;;^UTILITY(U,$J,358.3,16273,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16273,1,3,0)
 ;;=3^Hip Joint Replacement
 ;;^UTILITY(U,$J,358.3,16273,1,4,0)
 ;;=4^Z96.649
 ;;^UTILITY(U,$J,358.3,16273,2)
 ;;=^5063704
 ;;^UTILITY(U,$J,358.3,16274,0)
 ;;=Z96.659^^61^729^15
 ;;^UTILITY(U,$J,358.3,16274,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16274,1,3,0)
 ;;=3^Knee Joint Replacement
 ;;^UTILITY(U,$J,358.3,16274,1,4,0)
 ;;=4^Z96.659
 ;;^UTILITY(U,$J,358.3,16274,2)
 ;;=^5063708
 ;;^UTILITY(U,$J,358.3,16275,0)
 ;;=I69.90^^61^729^17
 ;;^UTILITY(U,$J,358.3,16275,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16275,1,3,0)
 ;;=3^Late Effects CVA
 ;;^UTILITY(U,$J,358.3,16275,1,4,0)
 ;;=4^I69.90
 ;;^UTILITY(U,$J,358.3,16275,2)
 ;;=^5007551
 ;;^UTILITY(U,$J,358.3,16276,0)
 ;;=I34.8^^61^729^19
 ;;^UTILITY(U,$J,358.3,16276,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16276,1,3,0)
 ;;=3^Mitral Valve Disorders NEC
 ;;^UTILITY(U,$J,358.3,16276,1,4,0)
 ;;=4^I34.8
 ;;^UTILITY(U,$J,358.3,16276,2)
 ;;=^5007172
 ;;^UTILITY(U,$J,358.3,16277,0)
 ;;=I23.0^^61^729^20
 ;;^UTILITY(U,$J,358.3,16277,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16277,1,3,0)
 ;;=3^Mural Thrombus
 ;;^UTILITY(U,$J,358.3,16277,1,4,0)
 ;;=4^I23.0
 ;;^UTILITY(U,$J,358.3,16277,2)
 ;;=^5007094
 ;;^UTILITY(U,$J,358.3,16278,0)
 ;;=I73.9^^61^729^22
 ;;^UTILITY(U,$J,358.3,16278,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16278,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,16278,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,16278,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,16279,0)
 ;;=Z86.79^^61^729^23
 ;;^UTILITY(U,$J,358.3,16279,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16279,1,3,0)
 ;;=3^Personal Hx of Circulatory System Disease NEC
 ;;^UTILITY(U,$J,358.3,16279,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,16279,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,16280,0)
 ;;=Z86.72^^61^729^24
 ;;^UTILITY(U,$J,358.3,16280,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16280,1,3,0)
 ;;=3^Personal Hx of Thrombophlebitis
